

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



July 24, 2024

National Stock Exchange of India Limited
Script Symbol: SUNPHARMA

BSE Limited
Script Code: 524715

Subject - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Additional Information on Dadra facility receives Warning Letter from USFDA

This is further to the intimation dated June 19, 2024, about the Company receiving a Warning Letter from USFDA for its Dadra facility. Vide said intimation, it was informed that the contents of the Warning Letter should be made public by the USFDA in due course.

Subsequently, the USFDA made the contents of the Warning Letter public, and it is available on its website.

In this connection, this is to inform further that there is no impact on the company's financial, operations, or other activities. We continue to work with the USFDA and undertake all necessary steps to resolve the outstanding issues.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983